By Julia Berends, Cord Kühnl, and Lucy Goodacre The New Researcher Network (NRN) was founded as … [Read More...] about The DDL New Researcher Network Expands its Activities
The DDL New Researcher Network Expands its Activities
Q&A with Copley’s Clair Brooks on in vitro testing for LGWP MDI reformulation
Copley Application Specialist Clair Brooks discusses new EMA guidance on data requirements … [Read More...] about Q&A with Copley’s Clair Brooks on in vitro testing for LGWP MDI reformulation
DDL 2023 highlighted novel technologies
The 34th iteration of the Drug Delivery to the Lungs (DDL) Conference, DDL 2023, drew approximately … [Read More...] about DDL 2023 highlighted novel technologies
Latest news
Kindeva appoints Jenifer Riter as VP of Analytical Services
Kindeva Drug Delivery has named former West Pharmaceutical Services Senior Director, Business and Technical Operations, Jennifer Riter as VP of Analytical Services. Earlier this year, Kindeva announced the launch of its new analytical services business, which will offer medical device, container … [Read More...] about Kindeva appoints Jenifer Riter as VP of Analytical Services
FDA approves Optinose’s Xhance nasal spray for the treatment of chronic sinusitis without nasal polyps
According to Optinose, the FDA has approved the company's sNDA to extend use of Xhance fluticasone propionate nasal spray to include the treatment of chronic sinusitis without nasal polyps. Xhance was approved by the FDA for the treatment of nasal polyps in 2017. Optinose submitted the sNDA in … [Read More...] about FDA approves Optinose’s Xhance nasal spray for the treatment of chronic sinusitis without nasal polyps
Aptar Pharma to add nasal delivery device manufacturing capacity
Device manufacturer Aptar Pharma announced that it will expand its production facility in Congers, NY, USA, including a significant increase in its capacity for manufacturing the Unidose (UDS) nasal delivery system. The expansion includes new cleanroom manufacturing, with additional molds and … [Read More...] about Aptar Pharma to add nasal delivery device manufacturing capacity
Inhalon publishes data from preclinical studies of its inhaled muco-trapping therapies in RSV and SARS-CoV-2 models
Inhalon Biopharma has announced the publication of two articles that present data from preclinical studies of the company's inhaled "muco-trapping" technologies. The first, published in the journal Advanced Science, describes a study of nebulized delivery of Inhalon's Mota-MT antibody to the lungs … [Read More...] about Inhalon publishes data from preclinical studies of its inhaled muco-trapping therapies in RSV and SARS-CoV-2 models
AstraZeneca initiates 2 Phase 3 trials investigating the effects of Breztri Aerosphere MDI on cardiopulmonary factors and outcomes in COPD patients
AstraZeneca today announced the initiation of the Phase 3 ATHLOS and THARROS trials evaluating the effects of Breztri Aerosphere budesonide / glycopyrronium / formoterol fumarate MDI on cardiopulmonary parameters and outcomes (including death) in COPD patients. Breztri was approved by the FDA for … [Read More...] about AstraZeneca initiates 2 Phase 3 trials investigating the effects of Breztri Aerosphere MDI on cardiopulmonary factors and outcomes in COPD patients
Other recent news
- MannKind presents data from Phase 4 trial of Afrezza inhaled insulin
- Vast announces appointments in preparation for clinical development of ALX1 inhalation solution
- Boehringer Ingelheim says it will limit out-of-pocket cost of its inhalers for some US patients
- UWA researchers get A$500,000 grant for development of Spritz-OM probiotic nasal spray for ear infections
- Iconovo gets Innowide grant to support marketing activities in South Korea